BridgeMD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children
EU CTIS ID: 2023-509134-19-00
What this study is testing
To evaluate the efficacy of SYD-101 for slowing the progression of myopia in children To evaluate the safety and tolerability of SYD-101
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Parent/guardian has the ability to understand the study informed consent form (ICF) and agrees to sign the ICF prior to initiation of any protocol-related procedures; participant has the ability to give assent, as applicable, at the time of parental/guardian consent
- BCVA of 75 letters (Snellen equivalent 20/32) or better
- Normal IOP <21 mmHg
- Participant is male or female between 3 and 14 years of age (inclusive) at the time of Screening
- Participant and parent/guardian are willing and able to comply with study instructions, study visits, and procedures
- Participant (or parent/guardian) has demonstrated ability to administer artificial eyedrops at the Screening or Baseline visit
You likely can't join if
- Participant is a female who is pregnant, lactating, or intending to become pregnant within next 4 years
- Use of any of the following (previously, currently, or plans to do so in the future): a) Orthokeratology (orthoK), rigid gas-permeable, bifocal, progressive-addition, multi-focal, or other lenses to reduce myopia progression b) Use of atropine, pirenzepine, or other anti-muscarinic agent for myopia
- History or evidence of any ocular surgery or planned future ocular surgery in either eye
- History or current evidence of ocular disease in the either eye that, in the opinion of the investigator, may confound assessment of visual acuity and/or refraction
- Unwillingness or inability to comply with study requirements and restrictions, including but not limited to those specified in Section 5.3 (eg, required conversion from extended wear lenses to daily wear lenses, full-time use of contact lenses or spectacles)
- Participant has a known allergy or hypersensitivity to atropine or any of the components of SYD-101
See the full eligibility criteria
Who can join
- Parent/guardian has the ability to understand the study informed consent form (ICF) and agrees to sign the ICF prior to initiation of any protocol-related procedures; participant has the ability to give assent, as applicable, at the time of parental/guardian consent
- BCVA of 75 letters (Snellen equivalent 20/32) or better
- Normal IOP <21 mmHg
- Participant is male or female between 3 and 14 years of age (inclusive) at the time of Screening
- Participant and parent/guardian are willing and able to comply with study instructions, study visits, and procedures
- Participant (or parent/guardian) has demonstrated ability to administer artificial eyedrops at the Screening or Baseline visit
- Participant is in good general health, with no clinically significant findings based on medical history and vital signs, as determined by the investigator at the time of Screening
- Postmenarchal female participants must have negative urine pregnancy test results
- Refractive error by cycloplegic autorefraction at the baseline visit: a) Myopia of 0.50 D to 6.00 D (inclusive) b) Astigmatism ≤1.50 D c) Anisometropia ≤1.00 D
- If the baseline myopia (SE) is <0.75 D, participant must have a history of myopia progression of 0.50 D in the previous 6 to 12 months
- If baseline myopia (SE) is ≥0.75 D, participant must be wearing refractive correction (single vision eyeglasses or soft, daily-wear, single-vision contact lenses) that meets the following criteria: a) Myopia (SE) corrected to within ±0.50 D of the investigator’s cycloplegic measurement of refractive error b) Cylinder power must be within ±0.50 D of the investigator’s standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction c) Cylinder axis must be within ±5 degrees of the axis found on the investigator’s standard refraction when cylinder power is ≥1.00 D or within ±15 degrees when the cylinder power is <1.00 D
What rules you out
- Participant is a female who is pregnant, lactating, or intending to become pregnant within next 4 years
- Use of any of the following (previously, currently, or plans to do so in the future): a) Orthokeratology (orthoK), rigid gas-permeable, bifocal, progressive-addition, multi-focal, or other lenses to reduce myopia progression b) Use of atropine, pirenzepine, or other anti-muscarinic agent for myopia
- History or evidence of any ocular surgery or planned future ocular surgery in either eye
- History or current evidence of ocular disease in the either eye that, in the opinion of the investigator, may confound assessment of visual acuity and/or refraction
- Unwillingness or inability to comply with study requirements and restrictions, including but not limited to those specified in Section 5.3 (eg, required conversion from extended wear lenses to daily wear lenses, full-time use of contact lenses or spectacles)
- Participant has a known allergy or hypersensitivity to atropine or any of the components of SYD-101
- Participant has history or current evidence of a medical condition predisposing the participant to degenerative myopia (eg, Marfan syndrome, Stickler syndrome) or a condition that may affect visual function or development (eg, diabetes mellitus, chromosome anomaly)
- One or more biological parents with a history of myopia ≥9.00 D
- Current use of a monoamine oxidase inhibitor
- History of, or currently receiving treatment for, any systemic infection or autoimmune disease considered serious by the investigator
- Participation in an investigational drug or device study within 30 days prior to Screening
- Evidence of any ocular inflammation or infection in either eye, including blepharitis, conjunctivitis, keratitis, and scleritis
- History or evidence of the following in either eye: a) Retinopathy of prematurity b) Abnormal refractive anatomy (eg, keratoconus, lenticonus, spherophakia) c) Amblyopia, manifest strabismus, or nystagmus
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.